Claudia Calcagno1,2, Carlos Perez-Medina1,2, Tina Binderup3, Mark E Lobatto4, Seigo Ishino1,2, Mootaz Eldib1,2, Philip Robson1,2, Sarayu Ramachandran1,2, Thomas Reiner5, Edward Fisher6, Zahi A Fayad1,2, and Willem JM Mulder1,2
1Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 2Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States, 3University of Copenaghen, Copenaghen, Denmark, 4Academisch Medisch Centrum, Amsterdam, Netherlands, 5Memorial Sloan Kettering Cancer Center, New York, NY, United States, 6New York University School of Medicine, New York, NY, United States
Abundant, active
inflammatory cells are a hallmark of high-risk atherosclerotic plaques.
High-density lipoprotein (HDL) is a natural nanoparticle composed of
phospholipids, cholesterol and apolipoprotein A-I (APOA1), which has been shown
to have atheroprotective properties. .
The recent development of combined PET/MRI scanners and new advances in radio-labeling
technology gives the opportunity to investigate theese properties in vivo. Using a unique
set-up combining PET/CT and PET/MRI, we non-invasively assess the
pharmacokinetics, distribution, metabolism and turnover of 89Zr-HDL’s in a rabbit model of atherosclerosis.
